MAR 20, 2018 9:00 AM PDT

Heart failure: A Global Challenge From Prognosis to Management

Sponsored by: Abbott Diagnostics
  • Vice Chief of Medicine, Baylor University Medical Center , and Principal Faculty in internal medicine, Texas A & M University Health Sciences Center
      After receiving a bachelor's degree from Baylor University, Dr. McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School in Dallas. He went on to complete his internal medicine residency at the University of Washington in Seattle, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master's degree in public health at the University of Michigan. Dr. McCullough is Vice Chief of Medicine at Baylor University Medical Center in Dallas, TX and is a Principal Faculty in internal medicine for the Texas A & M University Health Sciences Center. He is an internationally recognized authority on the role of chronic kidney disease as a cardiovascular risk state with over 1000 publications including the "Interface between Renal Disease and Cardiovascular Illness" in Braunwald's Heart Disease Textbook. Dr. McCullough is a recipient of the Simon Dack Award from the American College of Cardiology and the International Vicenza Award in Critical Care Nephrology for his scholarship and research. Dr. McCullough is a founder and current president of the Cardiorenal Society of America, an organization dedicated to bringing cardiologists and nephrologists together to work on the emerging problem of cardiorenal syndromes. His works have appeared in the New England Journal of Medicine, Journal of the American Medical Association, and other top-tier journals worldwide. He is the co-editor of Reviews in Cardiovascular Medicine, associated editor of the American Journal of Cardiology, and serves on the editorial boards of multiple specialty journals. Dr. McCullough has made presentations on the advancement of medicine across the world and has been an invited lecturer at the New York Academy of Sciences, the National Institutes of Health, U.S. Food and Drug Administration (FDA), European Medicines Agency, and the U.S. Congressional Oversight Panel.


    We are in the midst of a heart failure pandemic. There have been advances in medical and device therapy for patients with heart failure and reduced left ventricular ejection fraction.  In vitro diagnostic testing has been important in establishing prognosis as well as a guide to management.  Natriuretic Peptides are currently used in diagnosis, prognosis, screening, and response to treatment for patients with heart failure. Galectin-3 is another blood biomarker of heart failure. Its concentrations are prognostic for heart failure hospitalization and death.  Levels of natriuretic peptides and galectin-3 are complementary in clinical practice.

    After this webinar you will be able to;-

    • Describe the key challenges of Heart Failure
    • Discuss the differences between natriuretic peptides BNP and NT-proBNP for the diagnosis, stratification and management of Heart Failure
    • Understand the clinical utility and additive effect of Galectin-3 with natriuretic peptides for prognosis of Heart Failure

    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    NOV 18, 2020 8:00 AM PST
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    APR 01, 2021 8:00 AM PDT
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    NOV 16, 2020 8:00 AM PST
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    APR 21, 2021 10:00 AM PDT
    APR 21, 2021 10:00 AM PDT
    Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
    MAR 20, 2018 9:00 AM PDT

    Heart failure: A Global Challenge From Prognosis to Management

    Sponsored by: Abbott Diagnostics


    Laboratory Testing

    Clinical Chemistry

    Clinical Diagnostics


    Infectious Disease


    Cancer Research




    Cancer Diagnostics

    Molecular Biology



    Molecular Diagnostics


    North America67%



    South America3%


    Registration Source

    Website Visitors58%

    WAVE Newsletter Promotion17%

    Email Promotions15%

    Social Media Promotions7%

    Website Banners2%

    Trending Newsletter Promotion1%

    Job Title

    Medical Laboratory Technician16%

    Lab Management13%

    Facility/Department Manager13%

    Medical Doctor/Specialist10%



    Clinical Laboratory Scientist7%


    Research Scientist5%









    Clinical Laboratory14%

    Academic Institution8%

    Medical Device Company6%

    Biotech Company5%

    Medical School4%

    Medical Center4%


    Research Institute3%

    Industrial Company2%

    Pharmaceutical Company2%

    Physician Office Laboratory2%

    Ambulatory Care2%

    Life Science Company1%


    Show Resources
    Loading Comments...
    Show Resources
    • See more